Asahi Of Japan, NxStage Of U.S. In Pact To Market Dialysis Devices
This article was originally published in PharmAsia News
Executive SummaryJapan's Asahi Kasei Kuraray Medical and U.S.-based NxStage Medical have signed an exclusive licensing agreement for Asahi to produce and market NxStage devices in Asia. The pact also allows Asahi to market the devices in the rest of the world, but without exclusivity. The devices involved are disposable medical equipment used in home kidney dialysis. NxStage retained all rights to the equipment in North America. (Click here for more
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.